Medication adherence tied to lower cardiovascular risk

What happened: a 10-year look at adherence and heart risk

Researchers at the University of Copenhagen and collaborators tracked long-term diabetes medication adherence and later cardiovascular outcomes in people with type 2 diabetes.

Using Denmark’s national health registries, the team followed nearly 80,000 adults for 10 years and linked consistent use of prescribed glucose-lowering therapy with fewer major heart and circulatory complications.

• Paper: Long-term adherence to glucose-lowering therapy and cardiovascular risk in type 2 diabetes: a nationwide cohort study (The Lancet Regional Health – Europe, 2026)
• Population: 79,510 adults in Denmark newly diagnosed with type 2 diabetes
• Exposure: adherence patterns to noninsulin glucose-lowering medication over time, based on monthly pharmacy records

What the evidence shows about medication adherence and cardiovascular risk

This was a nationwide cohort study that grouped people into three adherence patterns using a statistical method applied to monthly pharmacy records over a decade.

Compared with high adherence, persistently low adherence was linked to higher rates of major cardiovascular events, and moderate adherence was linked to a smaller but still higher rate.

• Adherence patterns: ~41% high adherence, 33% moderate adherence, 26% persistently low adherence
• Major cardiovascular events: low adherence linked to a 27% higher rate vs consistent users; moderate adherence linked to a 7% higher rate
• Specific outcomes: low adherence linked to a 45% higher rate of ischemic heart disease and a 24% higher rate of stroke
• Time without serious heart/circulatory complications: consistent users stayed free for more than seven extra months vs those who did not

Medication adherence and cardiovascular risk in younger adults

The association between low adherence and cardiovascular risk was strongest among younger adults in this study.

Low adherence in younger adults was linked to a 73% higher rate of having a cardiovascular event before age 55 compared with consistent users.

• Finding highlighted by authors: developing type 2 diabetes early in life carries heavier lifetime risk to blood vessels, so early consistency may matter most during working and family years

Practical context for metabolic health: why people miss meds

The study suggests medication adherence is not only a “willpower” issue, because the low-adherence group was more likely to face social and health pressures.

After adjusting for factors such as living alone, lower income, and other chronic conditions, the researchers still found higher cardiovascular risk among people who were less adherent.

• Low-adherence group: more likely to live alone, have lower incomes, and manage other chronic conditions
• Author view (Jordi Merino, University of Copenhagen/CBMR): prescribing is only the first step; early personalized support after diagnosis may help
• Author view (Lise B. Nielsen, CBMR): health systems may need longer-term tracking than once-or-twice yearly checks to identify vulnerable patients earlier

Limitations and what this study can—and can’t—prove

This research was observational, so it identifies associations between adherence patterns and cardiovascular outcomes, not proof that improving adherence alone will prevent heart attack or stroke.

The study focused on adults in Denmark who were newly diagnosed with type 2 diabetes and started noninsulin glucose-lowering medication between 2005 and 2012, so results may not match other settings or treatment pathways.

• Design: nationwide cohort study using registry and pharmacy records, not a randomized trial
• Applies to: adults newly diagnosed with type 2 diabetes who started noninsulin medication in the study period
• Even with statistical adjustment for key social and health factors, residual confounding can remain in registry-based analyses